Wim Jiskoot

28.0k total citations · 5 hit papers
326 papers, 22.1k citations indexed

About

Wim Jiskoot is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wim Jiskoot has authored 326 papers receiving a total of 22.1k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Molecular Biology, 132 papers in Immunology and 78 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wim Jiskoot's work include Protein purification and stability (113 papers), Monoclonal and Polyclonal Antibodies Research (76 papers) and Immunotherapy and Immune Responses (71 papers). Wim Jiskoot is often cited by papers focused on Protein purification and stability (113 papers), Monoclonal and Polyclonal Antibodies Research (76 papers) and Immunotherapy and Immune Responses (71 papers). Wim Jiskoot collaborates with scholars based in Netherlands, United States and Germany. Wim Jiskoot's co-authors include Andrea Hawe, Daan J.A. Crommelin, Vasco Filipe, Joke A. Bouwstra, Wim E. Hennink, Gideon Kersten, Huub Schellekens, Marc Sutter, Bram Slütter and Koen van der Maaden and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Wim Jiskoot

324 papers receiving 21.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates

2010 1.4k citations Vasco Filipe, Andrea Hawe et al. Pharmaceutical Research profile →
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

2021 1.0k citations Gideon Kersten, Wim Jiskoot et al. profile →
Extrinsic Fluorescent Dyes as Tools for Protein Characterization

2008 973 citations Andrea Hawe, Wim Jiskoot et al. Pharmaceutical Research profile →
Microneedle technologies for (trans)dermal drug and vaccine delivery

2012 532 citations Koen van der Maaden, Wim Jiskoot et al. Journal of Controlled Release profile →
Addressing the Cold Reality of mRNA Vaccine Stability

2020 342 citations Daan J.A. Crommelin, Wim Jiskoot et al. Journal of Pharmaceutical Sciences profile →

Peers

Countries citing papers authored by Wim Jiskoot

Since Specialization

Citations

This map shows the geographic impact of Wim Jiskoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Jiskoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Jiskoot more than expected).

Fields of papers citing papers by Wim Jiskoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Jiskoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Jiskoot. The network helps show where Wim Jiskoot may publish in the future.

Co-authorship network of co-authors of Wim Jiskoot

This figure shows the co-authorship network connecting the top 25 collaborators of Wim Jiskoot. A scholar is included among the top collaborators of Wim Jiskoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Jiskoot. Wim Jiskoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intrinsic immunogenicity of liposomes for tuberculosis vaccines: Effect of cationic lipid and cholesterol 2024 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), Krista E. van Meijgaarden, Wim Jiskoot, Joke A. Bouwstra, Mariëlle C. Haks, Annemieke Geluk, Tom H. M. Ottenhoff	9
2	Cationic pH-sensitive liposomes as tuberculosis subunit vaccine delivery systems: Effect of liposome composition on cellular innate immune responses 2024 ·International Immunopharmacology ·(unknown), Krista E. van Meijgaarden, (unknown), Wim Jiskoot, Joke A. Bouwstra, Mariëlle C. Haks, Annemieke Geluk, Tom H. M. Ottenhoff	2
3	Noncovalent Conjugation of OVA323 to ELP Micelles Increases Immune Response 2024 ·Biomacromolecules ·(unknown), (unknown), Ye Zeng, René C. L. Olsthoorn, Grégory F. Schneider, Bram Slütter, J. Andrew MacKay, Wim Jiskoot, Alexander Kros	0
4	Uptake Kinetics Of Liposomal Formulations of Differing Charge Influences Development of in Vivo Dendritic Cell Immunotherapy 2022 ·Journal of Pharmaceutical Sciences ·Noémi Nagy, (unknown), (unknown), (unknown), Toni M.M. van Capel, (unknown), Yvette van Kooyk, Ronald van Ree, Sander W. Tas, Teunis B. H. Geijtenbeek, Wim Jiskoot, Bram Slütter, Esther C. de Jong	19
5	Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays 2022 ·Journal of Pharmaceutical Sciences ·Yu Tian, (unknown), Koen van der Maaden, (unknown), (unknown), Renate Akkerman, Conor O’Mahony, Wim Jiskoot, Henderik W. Frijlink, Anke Huckriede, Wouter L.J. Hinrichs, Joke A. Bouwstra, Martin Beukema	24
6	Bet v 1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet v 1 in a murine immunogenicity model 2022 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), (unknown), Lorenz Aglas, (unknown), (unknown), (unknown), J. Andrew MacKay, (unknown), Grégory F. Schneider, René C. L. Olsthoorn, Wim Jiskoot, Ronald van Ree, Alexander Kros	4
7	Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation 2018 ·PLoS ONE ·(unknown), Ninotska I. L. Derksen, (unknown), Simone Kruithof, Wim Jiskoot, Gestur Vidarsson, Theo Rispens	5
8	Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice 2018 ·Journal of Pharmaceutical Sciences ·Grzegorz Kijanka, Jared S. Bee, (unknown), Yuling Wu, Lorin Roskos, Mark A. Schenerman, Bram Slütter, Wim Jiskoot	56
9	Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines 2017 ·Cancer Immunology Research ·Eleni Maria Varypataki, Naomi Benne, Joke A. Bouwstra, Wim Jiskoot, Ferry Ossendorp	57
10	Original Research Nano-adjuvanted polio vaccine: Preparation and characterization of chitosan and trimethylchitosan (TMC) nanoparticles loaded with inactivated polio virus and coated with sodium alginate 2014 ·SHILAP Revista de lepidopterología ·Mohsen Tafaghodi, Gideon Kersten, Wim Jiskoot	3
11	Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo 2013 ·International Journal of Nanomedicine ·(unknown), Henri‐Pierre Lassalle, Aurélie François, Dominique Dumas, Sébastien Hupont, Susanna Gräfe, Vasco Filipe, Wim Jiskoot, François Guillemin, Vladimir Zorin, Lina Bezdetnaya	52
12	Micro–Flow Imaging and Resonant Mass Measurement (Archimedes) – Complementary Methods to Quantitatively Differentiate Protein Particles and Silicone Oil Droplets 2013 ·Journal of Pharmaceutical Sciences ·Daniel Weinbuch, Sarah Zölls, Michael Wiggenhorn, Wolfgang Frieß, Gerhard Winter, Wim Jiskoot, Andrea Hawe	101
13	Particles in Therapeutic Protein Formulations, Part 1: Overview of Analytical Methods 2011 ·Journal of Pharmaceutical Sciences ·Sarah Zölls, Ruedeeporn Tantipolphan, Michael Wiggenhorn, Gerhard Winter, Wim Jiskoot, Wolfgang Frieß, Andrea Hawe	186
14	On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis 2010 ·Journal of Interferon & Cytokine Research ·Miranda M. C. van Beers, Wim Jiskoot, Huub Schellekens	67
15	Microspheres of hydrophilic PLGA highly atractive for protein delivery 2010 ·Journal of Controlled Release ·Amir H. Ghassemi, Mies J. van Steenbergen, H. Talsma, Cornelus F. van Nostrum, Wim Jiskoot, Daan J.A. Crommelin, Wim E. Hennink	4
16	Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates breakdown → 2010 ·Pharmaceutical Research ·Vasco Filipe, Andrea Hawe, Wim Jiskoot	1417
17	Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery 2007 ·European Journal of Pharmaceutics and Biopharmaceutics ·Maryam Amidi, (unknown), Anne H. de Boer, Daan J.A. Crommelin, Wim E. Hennink, Wim Jiskoot	80
18	Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system 2005 ·Journal of Controlled Release ·Maryam Amidi, Stefan Romeijn, Gerrit Borchard, Hans E. Junginger, Wim E. Hennink, Wim Jiskoot	325
19	OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis 2004 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Marjan M. Fretz, Gerben A. Koning, Enrico Mastrobattista, Wim Jiskoot, Gert Storm	91
20	Solid‐phase synthesis and application of double‐fluorescent‐labeled lipopeptides, containing a CTL‐epitope from the measles fusion protein 1999 ·Journal of Peptide Research ·Peter Hoogerhout, Koert J. Stittelaar, Humphrey F. Brugghe, (unknown), G. J. ten Hove, Wim Jiskoot, (unknown), Paul Roholl	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact